-->

Tech Seeker (TS)

Acorda Therapeutics
Profile last edited on: 4/6/2022

Therapies for neurological disorders
TS Type
Small Corporation
Status
Active
Year Founded
1995
Last Involved Year
2013

Key People / Management

  Ron Cohen -- Founder & CEO

  Michael A Gesser -- Chief Financial Officer

  Lauren M Sabella -- Chief Operating Officer

Location Information

420 Saw Mill River Road
Ardsley, NY 10502
   (914) 347-4300
   www.acorda.com

Public Profile

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Extent of SBIR involvement

User Avatar

Synopsis: Techseeker Business Condition

Headquartered
USA
Employment
344
Revenue
$0.2M
Public/Private
Publicly Traded
Stock Info
NASDAQ : ACOR
Received SBIR $$
No

SBIR firms in the news

There are no news available.